ArticleAIDS patient care and STDs2012
Patient-reported symptoms on the antiretroviral regimen efavirenz/emtricitabine/tenofovir.
Article in AIDS patient care and STDs, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 33 citations in OpenAlex.
- Participant-reported Outcomes from the CAPELLA Clinical Trial of Lenacapavir-based Regimens in Heavily Treatment-experienced Adults with HIV.AIDS and behavior · 2025Trial
- Patient-Reported Outcomes in First-Line Antiretroviral Therapy: Results From NEAT001/ANRS143 Trial Comparing Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine or Raltegravir.Journal of acquired immune deficiency syndromes (1999) · 2018Trial
- Trial
- Self-Reported Side Effects and Adherence to Antiretroviral Therapy in HIV-Infected Pregnant Women under Option B+: A Prospective Study.PloS one · 2016Trial
- Trial
- Trial
- Long-term, bidirectional associations between depressive symptom severity and opioid use among people with HIV: A prospective cohort study.Addictive behaviors reports · 2025Article
- Psychometric characteristics of the Spanish version of the HIV Symptom Index.Journal of patient-reported outcomes · 2024Observational
- Prediction of adverse events risk in patients with comorbid post-traumatic stress disorder and alcohol use disorder using electronic medical records by deep learning models.Drug and alcohol dependence · 2024Article
- Prediction of Adverse Events Risk in Patients with Comorbid Post- Traumatic Stress Disorder and Alcohol Use Disorder Using Electronic Medical Records by Deep Learning Models.Research square · 2023Article
- Factors Associated with Bothersome Symptoms in Individuals With and Without HIV Who Report Alcohol Use.AIDS and behavior · 2023Article
- Patient-Reported Bothersome Symptoms Attributed to Alcohol Use Among People With and Without HIV.AIDS and behavior · 2022Article
- Self-Reported Cannabis Use and HIV Viral Control among Patients with HIV Engaged in Care: Results from a National Cohort Study.International journal of environmental research and public health · 2022Article
- A SMARTTT approach to Treating Tobacco use disorder in persons with HIV (SMARTTT): Rationale and design for a hybrid type 1 effectiveness-implementation study.Contemporary clinical trials · 2021Article
- Article
- Trajectories of Self-Reported Opioid Use Among Patients With HIV Engaged in Care: Results From a National Cohort Study.Journal of acquired immune deficiency syndromes (1999) · 2020Article
- Association of Alcohol Screening Scores With Adverse Mental Health Conditions and Substance Use Among US Adults.JAMA network open · 2020Article
- Opioid use trajectory groups and changes in a physical health biomarker among HIV-positive and uninfected patients receiving opioid agonist treatment.Drug and alcohol dependence · 2019Article
- Acute Liver Toxicity due to Efavirenz/Emtricitabine/Tenofovir.Case reports in hepatology · 2015Article
- EFV/FTC/TDF-associated hepatotoxicity: a case report and review.AIDS patient care and STDs · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Most patients (80-90%) newly diagnosed with HIV are started on the antiretroviral regimen efavirenz, emtricitabine, and tenofovir (EFV/FTC/TDF). Existing studies of patient tolerability, however, are limited. We compared symptom experiences of patients on EFV/FTC/TDF, and the subsequent impact on health-related quality of life, with those of patients on other combination antiretroviral therapy (cART). We conducted a cross-sectional analysis of the Veterans Aging Cohort Study from February 2008 to August 2009 to compare the symptom experiences of patients on EFV/FTC/TDF vs. other cART, unadjusted and then adjusted for treatment characteristics, and comorbid disease severity. We then assessed the association between EFV/FTC/TDF use and health-related quality of life. Among the 1,759 patients in our analytic sample, EFV/FTC/TDF use was associated with fewer symptoms than was other cART. The use of EFV/FTC/TDF was independently associated with health-related quality of life, and this association was at least partially explained by symptom burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.